These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33755163)

  • 41. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
    Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
    Trials; 2016 Apr; 17():199. PubMed ID: 27079511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
    Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?
    Downey M; Still C; Sharma AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Oct; 18(5):321-7. PubMed ID: 21878755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medicalisation of race.
    Duster T
    Lancet; 2007 Feb; 369(9562):702-4. PubMed ID: 17321318
    [No Abstract]   [Full Text] [Related]  

  • 47. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
    Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
    Gyawali B; Rome BN; Kesselheim AS
    BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
    Roginiel AC; Dhruva SS; Ross JS
    Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA warning targets OTC chelation products.
    Voelker R
    JAMA; 2010 Nov; 304(19):2112. PubMed ID: 21081718
    [No Abstract]   [Full Text] [Related]  

  • 51. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bidil: recontextualizing the race debate.
    Séguin B; Hardy B; Singer PA; Daar AS
    Pharmacogenomics J; 2008 Jun; 8(3):169-73. PubMed ID: 18195727
    [No Abstract]   [Full Text] [Related]  

  • 54. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time to welcome the elderly into clinical trials.
    Farkouh ME; Fuster V
    Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):673. PubMed ID: 18949002
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment for lupus, first in 50 years, offers modest benefits, hope to patients.
    Mitka M
    JAMA; 2011 May; 305(17):1754-5. PubMed ID: 21540415
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA Drug Trials Snapshots-A Clearer Picture.
    Dhruva SS; Redberg RF
    JAMA Intern Med; 2017 May; 177(5):727. PubMed ID: 28288250
    [No Abstract]   [Full Text] [Related]  

  • 58. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
    Temple R; Stockbridge NL
    Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New therapeutic agents marketed in 1995.
    Hussar DA
    Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.